Clinical trial
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
NCT00003176 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00003176 |
|---|---|
| Title | Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma |
| Official title | A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | carmustine, temozolomide |
| Enrollment | 82 |
| Start date | Mar 25, 1998 |
| Primary completion | Dec 3, 2001 |
| Completion | Jan 6, 2004 |
| First posted | Apr 7, 2004 |
| Last update posted | Jun 27, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: